key: cord-1038406-444c5gx9
authors: Bošnjak, Berislav; Odak, Ivan; Ritter, Christiane; Stahl, Klaus; Graalmann, Theresa; Steinbrück, Lars; Blasczyk, Rainer; Falk, Christine S.; Schulz, Thomas F.; Wedemeyer, Hans Heinrich; Cornberg, Markus; Ganser, Arnold; Förster, Reinhold; Koenecke, Christian
title: Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy
date: 2021-08-12
journal: Front Immunol
DOI: 10.3389/fimmu.2021.721738
sha: 73b5568134cb5703ca01cb7fd8a5ac592fd579b3
doc_id: 1038406
cord_uid: 444c5gx9

Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients.

The induction of antibodies binding to the receptor-binding domain (RBD) of the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has an important role in preventing virus infection and combating coronavirus disease 2019 (COVID-19) (1). In B cell deficient patients, who usually suffer from protracted COVID-19, convalescent plasma (CP) treatment proved to be helpful for controlling SARS-CoV-2 infection (2) (3) (4) (5) . However, the use of CP therapy in the treatment of immunoproficient patients with COVID-19 remains controversial. Although early meta-analyses indicated that prompt CP transfusion protects patients from lethal outcome (3) , recent randomized trials could not confirm this finding (6) .

Here, we describe the clinical course of a SARS-CoV-2 infection in a patient after CD19 CAR-T immunotherapy (CART) who had complete B cell depletion. Interestingly, the patient was able to contain the infection for five weeks but then developed aggravated symptoms leading to hospitalization. The symptoms rapidly resolved upon treatment with CP, which coincided with increase in SARS-CoV-2-specific T cell responses, natural killer (NK) cell maturation and decreased plasma levels of IL-6 and CXCL10. Overall, these data suggest an important role of SARS-CoV-2-specific antibodies in aiding endogenous NK and T cell responses to control SARS-CoV-2 infections.

A female patient received CD19 CART (Tisagenlecleucel) for the treatment of refractory diffuse large B-cell lymphoma on March 23, 2020, which led to complete remission of the lymphoma. Observed long-term side effects of CART were secondary hypogammaglobulinemia and prolonged pancytopenia. Hence, the patient received monthly intravenous immunoglobulin (IVIG), blood transfusions and intermittent G-CSF administration. IVIG treatment consisted of 10g Ig vena © , a commercially available pooled unspecific polyclonal human IgG serum (IgG1 62.1% IgG2 34.8%, IgG3 2.5%, IgG4 0.6%, IgA <50µg/mL), while the G-CSF (5µg/kg body weight/day) was administered intermittently in the months after CART when the neutrophil count was <500/µl. Eight months after CART, she tested positive for SARS-CoV-2 in an outpatient setting. Initial COVID-19 symptoms were mild, including fever, anosmia, ageusia and weight loss. The ongoing pancytopenia was aggravated, requiring platelet transfusions at a higher frequency. The patient was in home isolation and regularly seen by her local oncologist. Mild symptoms persisted over the next five weeks when she was ( Figure 1A and Table 1 ). She was admitted to the specialized COVID-19 ward of Hannover Medical School 48 days postsymptom onset (PSO) due to aggravating clinical symptoms, in particular fever and cough. Due to low neutrophil counts on day of admittance, the patient received a single dose of G-CSF (5µg/ kg bodyweight). SARS-CoV-2 infection was confirmed in house and viral genome sequencing (for details see Supplementary Materials) indicated that SARS-CoV-2 was of the B.1.36 lineage (Supplementary Figure 1) . A chest CT scan showed COVID-19 pneumonia ( Figure 1B) . Of note, no oxygen support was required. The CT scan and bone marrow evaluation confirmed ongoing complete remission of the lymphoma. Bone marrow cytology showed a hypocellular marrow consistent with toxic damage. A complete B cell deficiency was demonstrated by flow cytometry on peripheral blood and bone marrow at the time of SARS-CoV-2 infection ( Figure 1C) . Therefore, the patient received (unspecific) IVIG treatment post hospitalization. At day 63 PSO, due to recurrent febrile episodes and undulating viral loads in nasopharyngeal swabs, the patient was also transfused with 295 ml of SARS-CoV-2 CP with neutralizing capacity of >90% and titer of >1:100 with according to SARS-CoV-2 S protein-pseudotyped-vesicular stomatitis virus vector-based neutralization assay (7, 8) . Within one week of CP treatment viremia decreased, the patient's condition rapidly improved and fever subsided. Resequencing of a PCR-positive respiratory sample taken 68 days PSO showed that the virus had acquired a V127I substitution in the N-terminal domain of the S protein (Supplementary Figure 1) . The patient was discharged on day 70 PSO to home isolation and continuous outpatient control. Within one week after hospital discharge, the viral load in nasopharyngeal swabs increased. Nevertheless, the patient remained asymptomatic and did not receive any additional treatments. At 3 months PSO, pancytopenia resolved and viral load in nasopharyngeal swabs decreased and 4 months PSO, the patient tested negative for SARS-CoV-2 ( Figure 1A ) and was free of any COVID-19 symptoms.

The institutional review board approved this study (No. 8610-BO-K-2019). Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article. Neutralizing anti-SARS-CoV-2-S antibodies in plasma were determined by a surrogate virus neutralization test (sVNT) as described (7) . Patient blood and bone marrow was analyzed using flow cytometry. For T cell reactivation, PBMCs were stimulated ex vivo with overlapping peptide pools from indicated SARS-CoV-2 proteins. Intracellular cytokine expression was analyzed afterwards. All details are described in Supplementary Materials.

As expected, no anti-SARS-CoV-2-RBD antibodies in the IVIG preparation or patient's plasma pre-CP could be detected by sVNT ( Figure 1D ). However, in pre-CP blood of the patient we detected presence of CD3 − CD56 − CD16 + NK cells, a NK population that recently engaged target cells (9)( Figure 1E) . Moreover, in blood we also detected CD8 + and CD4 + T cell responses specific to SARS-CoV-2 spike (S), or membrane (M), nucleocapsid (N) and envelope (E) proteins ( Figure 1F) . Interestingly, at this time point antigen-specific CD4 + T cells predominantly produced TNF-a, while CD8 + T cells predominantly produced IFN-g ( Figure 1G and Supplementary Figure 2 ). Together, these data indicated that the patient's cellular immune response was sufficient to contain but inadequate to clear the infection.

Post-CP, the neutralizing antibodies were measurable in the patient's plasma for a week, albeit at very low levels ( Figure 1D ). The clinical improvement post-CP was accompanied by a rapid decrease of plasma IL-6 and CXCL10 ( Figure 1H and Table 1 ) as well as marked expansion of SARS-CoV-2 S-and MNE-specific CD8 + and CD4 + T cell populations ( Figure 1F and Supplementary Figure 2) . Importantly, a markedly increased proportion of the antigen-specific CD8 + and CD4 + T cells simultaneously produced TNF-a and IFN-g, indicating their activation and/or maturation ( Figure 1G ). Post-CP we also observed a strongly increased frequency of recently activated CD16 + CD56 -NK cells ( Figure 1E ). Together, these data suggest that the CP therapy, in addition to directly neutralizing SARS- 

Interestingly, we detected a peak of inflammatory cytokines in plasma post hospital release ( Figure 1H and Supplementary Table 1) , suggesting a second wave of immune response activation. Of note, at this time we detected a higher percentage of anti-SARS-CoV-2 MNE-specific CD8 + and CD4 + T cells than anti-SARS-CoV2 S-specific T cell populations ( Figure 1F and Supplement Figure 2) . Moreover, the antigenspecific T cells again predominantly one cytokine, suggesting resolution of the acute immune response ( Figure 1G ).

Here, we described the case of a B cell deficient patient after CD19 CART with protracted COVID-19. For weeks, this patient only inefficiently contained the virus while CP transfusion correlated with virus clearance. Interestingly, increased anti-SARS-CoV-2 T cell and NK cell responses coincided with plasma transfusion, presumably also contributing to the patient's recovery.

The mechanisms of CP action could be multifaceted. Besides neutralizing antibodies, CP contains other components that could block pro-inflammatory cytokines, reduce complement activation, or provide direct antiviral effects (10, 11) . Nevertheless, the fact that clinical benefits of CP positively correlate with titers of neutralizing plasma antibodies (3, 10, 12) suggests that the main mode of CP action by providing supplementation with neutralizing antibodies. In line with this hypothesis, supplementation with anti-SARS-CoV-2 monoclonal neutralizing antibodies also provides direct antiviral effects, reduces viral loads and restrains the infection, while at the same time allows precise neutralizing antibody dosing (13) . Interestingly, our observation of coinciding activation of NK cells and SARS-CoV-2-specific T cells after plasma therapy suggests additional mechanisms that helped to finally clear the infection. CP contains also antibodies targeting different viral proteins that contribute to the activation of NK cells by inducing antibodydependent cell cytotoxicity (ADCC) (14) . Alternatively, these antibodies could kill infected cells by stimulating complementdependent cytotoxicity (CDC) (15) . Additionally, these antibodies could contribute to antibody-dependent cellular phagocytosis (ADCP) and increased antigen presentation to T cells, which is in line with reports that antibodies have essential complementary roles to CD8 + T cells in protection against viral infections (16, 17) . In line with those reports, we observed markedly expanded CD8 + and CD4 + SARS-CoV-2-specific T cells following CP therapy. Similarly to the data from our patient, a previous case report of a SCID patient also showed that an initial CP treatment suppressed SARS-CoV-2 viremia and enabled a successful allogeneic stem cell transplantation (4). However, SARS-CoV-2 infection was cleared only after successfully restoring T and NK cell functionality (4). On the other hand, another patient who became infected with SARS-CoV-2 25 days after receiving CAR T cells targeting the B cell maturation antigen for the treatment of multiple myeloma, succumbed to COVID-19 despite receiving CP and multiple other treatments (18) . Of note, this patient received CP therapy shortly after lympho-depleting immunotherapy and on a second occasion, CP therapy was combined with immunosuppressive treatment with dexamethasone (18) . It seems possible, therefore, that a high dose steroid treatment might have suppressed beneficial effects of CP on anti-SARS-CoV-2 T cell activation. In line with this hypothesis are findings of no additional benefits o f C P o v e r p l a c e b o w h e n a p p l i e d t o g e t h e r w i t h corticosteroids (19) .

Of note, unopposed by fully functional immune system, the SARS-CoV-2 infection persisted for several months allowing the time to virus to accumulate different mutations. Hence, our data 

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

The studies involving human participants were reviewed and approved by Hannover Medical School review board approved this study (No. 8610-BO-K-2019). The patients/participants provided their written informed consent to participate in this study.

BB, IO, CR, CF, and LS performed experiments. KS, TG, MC, HW, AG, and CK were involved in the treatment of the patient. RB provided essential reagents. TS, RF, and CK supervised lab work. BB, RF, and CK designed the study and wrote the manuscript. All authors contributed to the article and approved the submitted version. 

Immunology of COVID-19: Current State of the Science

Convalescent Plasma Therapy for B-Cell-Depleted Patients With Protracted COVID-19

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-Analysis

SARS-CoV-2 Infection Associated With Hepatitis in an Infant With X-Linked Severe Combined Immunodeficiency

Treatment of B-Cell Depleted COVID-19 Patients With Convalescent Plasma and Plasma-Based Products

Convalescent Plasma in Patients Hospitalised With COVID-19

Low Serum Neutralizing Anti-SARS-CoV-2 S Antibody Levels in Mildly Affected COVID-19 Convalescent Patients Revealed by Two Different Detection Methods

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

CD56negCD16+ NK Cells Are Activated Mature NK Cells With Impaired Effector Function During HIV-1 Infection

Convalescent Plasma in Covid-19: Possible Mechanisms of Action

COVID-19 Convalescent Plasma: Mechanisms of Action and Rationale for Use: A Narrative Review

Convalescent Plasma Antibody Levels and the Risk of Death From COVID-19

Neutralizing Monoclonal Antibodies for Treatment of COVID-19

Presence of Antibody-Dependent Cellular Cytotoxicity (ADCC) Against SARS-CoV-2 in COVID-19 Plasma

Dissecting Antibody-Mediated Protection Against SARS-CoV-2

Antibodies and CD8 + T Cells Are Complementary and Essential for Natural Resistance to a Highly Lethal Cytopathic Virus

Cooperativity Between CD8+ T Cells, non-Neutralizing Antibodies, and Alveolar Macrophages Is Important for Heterosubtypic Influenza Virus Immunity

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus

Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Convalescent Plasma in Patients Admitted to Hospital With COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial

We thank Melanie Drenker, Abdi Demera, Kerstin Beushausen, and Jana Keil for technical assistance and Stephan Halle for critical reading of the manuscript.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.